A Novartis cross-border partnership is turning into a standoff. The Swiss pharma has unilaterally terminated a plant leasing contract with Chinese CDMO Porton Pharma Solutions after a regulatory hiccup. More: Novartis terminates plant contract with Chinese CDMO Porton, threatens M
read moreFollowing a string of defeats for the industry in challenging the Inflation Reduction Act, Hail Mary efforts from a handful of companies to have their criticisms heard by the United States’ High Court have fallen flat. More: Supreme Court declines
read moreAfter an impressive phase 3 showing last fall, AstraZeneca’s wager on CinCor Pharma and its aldosterone synthase inhibitor (ASI) baxdrostat has continued to pay off, with an FDA approval Monday that also advances the British pharma’s goal to strike $80
read moreMerck and Kelun-Biotech have already notched four approvals in China for their TROP2-directed ADC sacituzumab tirumotecan. Now, after meeting the primary endpoints in a phase 3 trial of certain patients with endometrial cancer, the companies are taking steps to gain
read moreAlready tracking $5 billion in annual sales, Enhertu has secured two new FDA approvals for treating early breast cancer. But while arriving nearly two months early, the adjuvant label comes with a catch. More: Daiichi, AstraZeneca’s Enhertu breaks into early
read more
Parsortix platform to support minimally invasive analysis across various cancer trials More: Cellbxhealth partners with AdventHealth on CTC‑based monitoring in two major cancer studies Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals